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Poorer European Countries are Less Concerned
about Biotechnology than Richer Countries*
Michael Siegrist
Introduction
It is widely agreed among genetic engineers and scientists that
attitudes held by the public will strongly affect the future development
of genetic engineering. 1 In democratic societies, the public will have
an impact on new laws regulating biotechnology, influencing, for
example, decisions on the labeling of genetically modified products.
Ultimately, consumer behavior will determine which new products will
be accepted and economically successful.
There is no agreement among experts on how to address concerns
about biotechnology applications. Some experts argue that the public
should be informed about the risks and benefits of genetically
engineered food to enable them to make rational choices. 2 Other
experts contend that biotechnology food is no different from
traditional food and that distinguishing labels would be misleading.3
It is important, therefore, to identify the factors that influence people's
perceptions of the risks and their acceptance or rejection of this new
technology. Without such knowledge, there is no way to bridge the gap
between the public and the scientists or biotechnology companies.
* The article is based on work supported by the Swiss National Science Foundation under
grant #8210-053512. The author also gratefully acknowledges the comments on earlier drafts
provided by Dr. Timothy C. Earle and three anonymous reviewers.
** Dr. Siegrist wrote the present article during a stay as a visiting researcher at the Western
Institute for Social Research, Psychology Department, Western Washington University,
Bellingham, WA. He received his Ph.D. in Psychology from the University of ZUrich,
Switzerland. He is currently at the Department of Psychology, University of Zdrich,
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I See Isaac Rabino, How European and U.S. Genetic Engineering Scientists View the
Jmpact of Public Attention on Their Field: A Comparison, 19 Sci. Tech. Human Values 23
(1994).
2 See Lynn J. Frewer, Chaya Howard & Richard Shepherd, Effective Communication
About Genetic Engineering and Food, 98 Brit. FoodJ. 48 (1996).
3 See Henry I. Miller, A Rational Approach to Labeling Biotech-derived Foods, 284 Sci.
1471 (1999).
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Perception of Gene Technology
Perception and acceptance of gene technology vary according to its
type of application. 4 Surveys in both the United States and Europe
have shown stronger support for medical applications than for
agricultural applications. In a study conducted by Siegrist and
Biihlmann, participants rated the similarity of all possible pairs among
fifteen scenarios involving different applications of gene technology
drawn from agricultural, food-related, and medical applications.
Multidimensional scaling showed that two dimensions were relevant to
the perception of gene technological applications. The first dimension
was related to the nature of the application (food related/medical
applications). Participants assessed medical applications as more
beneficial and more acceptable than food applications. The second
dimension was related to the organisms involved (animals,
plants/micro-organisms). Participants judged applications involving
animals or plants to be riskier than applications involving micro-
organisms. Despite the observed mean differences among applications,
strong correlations for perceived benefits, perceived risks and
acceptance among different applications were observed. 5
People who trusted public authorities perceived gene technology
more positively than those who showed a low level of trust.6 Using a
structural modeling approach, it has been shown that trust in the
institution or researchers involved in using or regulating biotechnology
was positively related to perceived benefits and inversely related to
4 See Lynn J. Frewer, Chaya Howard & Richard Shepherd, Public Concerns in the United
Kingdom About General and Specific Applications of Genetic Engineering: Risk, Benefit, and
Ethics, 22 Sci. Tech. Human Values 98 (1997); George Gaskell et al., Worlds Apart? The
Reception of Genetically Modified Foods in Europe and the U.S., 285 Sc. 384 (1999);
Thomas J. Hoban, Consumer Acceptance of Biotechnology in the United States and Japan, 53
Food Tech. 50 (1999); Michael Siegrist & Renate Bijhlmann, Die Wahrnehmung
verschiedener gentechnischer Anwendungen: Ergebnisse einer MDS-Analyse, 30 Zeitschrift fiir
Sozialpsychologie 32 (1999); Bernhard Zechendorf, What the Public Thinks About
Biotechnology, 12 Bio/Tech. 870 (1994).
5 See Michael Siegrist, A Causal Model Explaining the Perception and Acceptance of Gene
Technology, 29 J. Applied Soc. Psych. 2093 (1999) [hereinafter A Causal Model]; Michael
Siegrist, The Influence of Trust and Perceptions of Risks and Benefits on the Acceptance of
Gene Technology, 20 Risk Analysis 195 (2000) [hereinafter The Influence of Trust].
6 See Biotechnology and the European Public Concerted Action Group, Europe
Ambivalent on Biotechnology, 387 Nature 845 (1997) [hereinafter Concerted Action Group];
Paul Sparks, Richard Shepherd & Lynn J. Frewer, Gene Technology, Food Production, and
Public Opinion: A UK Study, 11 Agric. Hum. Values 19 (1994).
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perceived risks of the technology.7 Furthermore, acceptance of gene
technology was strongly influenced by its perceived benefits and
perceived risks. 8 In other words, social trust had an indirect influence
on acceptance of biotechnology. 9 Most people do not possess
detailed knowledge of gene technology. 10 Due to this lack of
knowledge, people do not directly assess benefits and risks associated
with biotechnology. Instead, lay people will base their assessments on
information provided by sources they trust.
Most of the past research has focused on individual differences in
either perception of the technology" 1 or on perception of different
applications of the technology. 12 For example, surveys conducted in
several European countries indicate that there are differences in the
perception and the support of biotechnology across Europe. 13 It is still
an open question, however, why people in some countries are concerned
about gene technology while people in other countries are not.
Economics and Risk Perception
Some researchers have emphasized the influence of cultural variables
in risk perception and acceptance. 14 According to this view,
differences in risk perceptions can be explained by specific cultural
biases. Empirical studies have shown low correlations between such
cultural biases or worldviews and the risks that people were concerned
7 See A Causal Model & The Influence of Trust, supra note 5.
8 See A Causal Model & The Influence of Trust, supra note 5.
9 See Timothy C. Earle & George T. Cvetkovich, Social Trust- Toward a Cosmopolitan
Society (1995).
10 See Biotechnology in the Public Sphere (John Durant et al. eds., 1998) [hereinafter
Durant et al.].
11 See Michael Siegrist, Belief in Gene Technology: The Influence of Environmental
Attitudes and Gender, 24 Pers. Ind. Diff. 861 (1998); A Causal Model & The Influence of
Trust, supra note 5; Sparks et al. supra note 6; Paul Sparks, Richard Shepherd & Lynn J.
Frewer, Assessing and Structuring Attitudes Toward the Use of Gene Technology in Food
Production: The Role of Perceived Ethical Obligation, 16 Basic App. Soc. Psych. 267 (1995).
12 See Frewer et al., supra note 4; Siegrist & Biihlmann, supra note 4.
13 See Concerted Action Group, supra note 6; Durant er al., supra note 10; European
Commission Eurobarometer Unit, The Europeans and Modem Biotechnolog, Eurobarometer
46.1 (1997).
14 See Mary Douglas & Aaron Wildavsky, Risk and Culture: An Essay on the Selection of
Techmological and Environmental Dangers (1982); Aaron Wildavsky, No Risk is the Highest
Risk of All, 67 Am. Scientist 32 (1979); Aaron Wildavsky & Karl Dake, Theories of Risk
Perception: Who Fears What and Why?, 119 Daedalus 41 (1990).
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about. 15 One possible explanation for differences in risk perception
across countries is that countries may differ in respect to differences in
prevalent cultural biases. Another view is that economic factors
determine risk perception and acceptance. 16 One possible explanation
for differing perceptions of gene technology may be variations in
economic development. It has been suggested that acceptance of
biotechnology may be higher in poorer than in richer European
countries.17 This hypothesis, however, has yet to be tested.
People in poorer countries may be more willing to accept
technological risks because the relative gain associated with
technological developments is higher there than for people in richer
countries. There is a diminishing marginal utility of the benefits of new
technologies. Therefore, people in richer countries may perceive less
benefits in a technology than people in poorer countries.
Sokolowska and Tyszka recently addressed this hypothesis. 18
They predicted that, in comparison with Sweden, technologies in
Poland would be viewed as more beneficial and less risky. Contrary to
this hypothesis, however, respondents in Poland assessed the risks
connected with the hazards as higher than respondents in Sweden. In
both countries actual levels of risks associated with the hazards are
different. Based on the data provided by Sokolowska and Tyszka, it is
not possible to decide whether Poles overestimated or underestimated
the risks associated with the hazards. 19 Personal benefits associated
with different technologies were judged to be higher in Sweden than in
Poland. However, participants in Poland showed less negative attitudes
towards the technological hazards than participants in Sweden. This
suggests, according to the authors, that acceptance of risky technologies
is not solely determined by perceived risks and benefits.
15 See Jean Brenot, Sylviane Bonnefous & Claire Marris, Testing the Cultural Theory of
Risk in France, 18 Risk Analysis 729 (1998); Claire Marris, Ian H. Langford & Timothy
O'Riordan, A Quantitative Test of the Cultural Theory of Risk Perceptions: Comparison with
the Psychometric Paradigm, 18 Risk Analysis 635 (1998); Lennart Sj6berg, Factors in Risk
Perception, 20 RiskAnalysis 1 (2000).
16 See Joanna Sokolowska & Tadeusz Tyszka, Perception and Acceptance of Technological
and Environmental Risks: Why are Poor Countries Less Concerned?, 15 Risk Analysis 733
(1995).
17 See Durant et al., supra note 10.
18 See Sokolowska & Tyszka, supra note 16.
19 Id.
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Rationale of the Present Study
Few studies have investigated the relationship between economic
wealth and perception of hazards. The present study tested the
hypothesis that acceptance of biotechnology in Europe is negatively
related to the wealth of a country. The same relationship was expected
for perceived benefits of gene technology. In addition, it was expected
that people in richer countries perceive greater risks associated with gene
technology than people in poorer countries. Finally, it was hypothesized
that in richer countries the news media focus more on risks and less on
benefits associated with biotechnology than in poorer countries. In
other words, the new technology is portrayed in a more positive way in
poorer countries than in richer countries.
Method
Data drawn from a European survey of public perception of
biotechnology were used for a secondary analysis. 2 0 The survey was
conducted in all fifteen member states of the European Union
(Belgium, Denmark, Germany, Greece, Italy, Spain, France, Ireland,
Luxembourg, Netherlands, Portugal, United Kingdom, Finland,
Sweden, and Austria), Norway, and Switzerland. A multi-stage,
random sampling procedure was used. The sample size varied between
610 (Luxembourg) and 2,032 (Germany). Only persons aged fifteen
and over participated in the survey. Interviews were carried out face-to-
face in November 1996 (except Switzerland, June 1997).
Participants were asked whether they perceived six gene technology
applications as useful for society, risky, and morally acceptable; they
were also asked whether applications should be encouraged. Of the six
gene technology applications, two were related to food 21 and four
were related to medical applications. 22 Four-point Likert scales were
20 See Concerted Action Group, supra note 6; Durant et al., supra note 10; European
Commission Eurobarometer Unit, supra note 13.
21 The two items measuring usefulness of food applications read: "Useful for society to use
modern biotechnology in the production of foods, for example to make them higher in protein,
keep longer or change taste?" and "Useful for society to take genes from plant species and
transfer them into crop plants, to make them more resistant to insect pests?"
22 The four items measuring usefulness of medical applications read: "Useful for society to
introduce human genes into bacteria to produce medicines or vaccines, for example to produce
insulin for diabetics?"; "Useful for society to develop genetically modified animals for
laboratory research studies, such as a mouse that has genes which cause it to develop cancer?";
"Useful for society to introduce human genes into animals to produce organs for human
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used to measure the four constructs ("definitely agree" coded as 2 to
"definitely disagree" coded as -2).23 The "don't know" category was
coded as 0. In the present study, mean scores across the two food
applications and across the four medical applications were used.24 Past
research suggests that medical applications are viewed more positively
than food applications, so the two categories were analyzed
separately. 25
Results of a content analysis of articles about biotechnology
between 1973 and 1996 were presented by Durant et al.2 6 In the
twelve participating countries (United Kingdom, France, Germany,
Netherlands, Austria, Sweden, Greece, Denmark, Italy, Finland,
Switzerland, Poland), one or up to three print media with opinion
leader functions were analyzed. A sample of articles was selected for a
content analysis. 27 The authors report for each country the percentage
of articles that mentioned risks only, benefits only, risks as well as
benefits, and neither risks nor benefits. For the present study, the
relevant data consists of the percentage of articles reporting the risks but
not benefits associated with biotechnology and the percentage of
articles reporting the benefits but not risks associated with gene
technology.28
The Gross National Product (GNP) per capita for 1997, in dollars,
was used as an indicator of each country's wealth.2 9 The GNP per
capita reflects a country's average income per person. It may be
transplants, such as into pigs for human heart transplants?"; and "Useful for society to use
genetic testing to detect diseases we might have inherited from our parents such as cystic
fibrosis, mucoviscidosis or thalassaemia?"
23 The question measuring the four constructs read: "Do you definitely agree, tend to agree,
tend to disagree or definitely disagree that it is useful for society to (...)"; "(...) that it is risky to
(...)"; "(...) that it is morally acceptable to (...)" and "(...) that society should be encouraged to
V...)."
24 See Durant et al., supra note 10, at 259-260, Tables Sa to 8d.
25 See Siegrist & Bihlmann, supra note 4.
26 See Durant et al., supra note 10.
27 See id. at 276-298, Appendix 3 to Appendix 7, for a detailed description of the
procedure. The sample consisted of 5,404 articles published in nineteen newspapers or
magazines. The average intercoder agreement was 68% for benefit and 77%0 for risk.
28 See id. at 294, Table 8.
29 See http://www.worldbank.org/data/databyropic/GNPPC97.pdf. It was assumed that
the economic development of the near future is more important than past developments.
Therefore, the GNP 1997 was used. This assumption is not critical, however, because the GNPs
of different years are highly correlated.
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problematic to compare GNP per capita across countries because the
purchasing power of the dollar may differ. Purchasing power parity
(PPP), on the other hand, reflects the actual purchasing power per
capita. However, GNP and PPP were highly correlated (rs = .92, p <
.001);30 therefore, analyses using PPP instead of GNP yielded
virtually identical results. In the present article only results of the
analyses using GNP per capita are presented.
Results
Due to the small number of data points, possible outliers could have
a strong influence on correlation coefficients. Therefore, rank
correlation coefficients were computed. Rank correlations between
GNP and risk, usefulness, moral acceptability and encouragement of
gene technology for food and medical applications are shown in Table
1. A significant correlation between GNP and perceived risks was
observed for food applications but not for medical applications. People
in richer countries perceived more risks associated with genetically
modified food than people in poorer countries. No such differences
were found for medical applications, which are generally assessed more
positively. GNP correlated negatively with perceived usefulness, moral
acceptability, and encouragement. Food related applications had a
somewhat higher correlation than medical applications. Altogether,
people in poorer countries assessed biotechnology more positively than
people in more developed countries.
Table 1
Rank Correlations Between GNP per Capita, Risk, Usefulness, Moral Acceptability, and







*p<.06 **p<. 0 5 ***p.01
30 See id. for source of PPP values. For Luxembourg, the PPP was not available. The
analyses were, therefore, based on sixteen instead of seventeen countries.
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Rank correlations between mean assessments of risk, usefulness,
moral acceptability and encouragement for food and medical
applications are shown in Table 2. Perceived risks of food applications
were negatively correlated with usefulness, moral acceptability and
encouragement. However, no significant correlations between risk and
any other variable were found for medical applications. The strong
intercorrelations between usefulness, moral acceptability and
encouragement suggest that these three items measured the same latent
construct. Further support for this interpretation stems from results
found on the level of the individual subjects, which also yielded high
correlations among the three variables.3 1
Table 2
Rank Correlations Between Risk, Usefulness, Moral Acceptability, and Encouragement for
Food and Medical Applications (N= 17)
1 2 3 4 5 6 7 8
Risk Risk Useful Useful Moral Moral Encour. Encour.
Food Med. Food Med. Accep. Accep. Food Med.
Food Med.
1 Risk food x
2 Risk medicine .42* x
3 Usefulness food -.44* .26 x
4 Usefulness medicine -.27 -.07 .55*' x
5 Moral acceptability food -.55** .26 .90*** .51' x
6 Moral acceptability medicine -.27 .16 .47* .76*** .58** x
7 Encouragement food -.65*** .16 .91*** .59** .97*** .61.* x
8 Encouragement medicine -.49** .02 .59** .87*** .67*** .89*** .73*** x
*p<.10 **p<.05 ***p- O1
Rank correlations between GNP per capita and the percentage of
the articles reporting either risks or benefits were computed to test the
hypothesis that the wealth of a country influences how newspapers cover
gene technology. Data from a content analysis were available for twelve
European countries. The expected association was observed between
GNP and the percentage of articles in which risks but not benefits were
reported, rs = .79, p < .005 (N = 12). A negative association was found
between GNP and the percentage of articles in which benefits but not
risks were reported, rs = -.70, p < .02 (N = 12). The two indices,
percentage of risk-related articles and percentage of benefit-related
31 See Durant et al., supra note 10.
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articles, were significantly correlated, rs = -.86, p < .001 (N = 12). In
other words, these results show that, in richer countries, newspapers
reported more critical stories about biotechnology than in poorer
countries.
Conclusion
The wealth of a country had an influence on perceived risks
associated with genetically modified food. However, no such
association was observed for medical applications. Results only partially
support the hypothesis that economic wealth influences risk perception.
GNP was strongly negatively correlated to perceived usefulness and
acceptability of gene technology. This inverse relationship was observed
for food-related applications as well as for medical applications.
Altogether, people in poorer countries were more inclined to neglect
possible risks and to focus on benefits associated with the new
technology.
The results of the present study suggest that the economic context
may have an impact on the level of risks tolerated in a society. These
findings are in line with the conclusion of Sokolowska and Tyszka that
poorer societies are more willing to accept risks associated with
technologies than are richer societies. 3 2 This may be a rational
response; there is a diminishing marginal utility of the benefits
associated with economic progress. In relative terms, people in poorer
countries may benefit more from technological and economical
developments than people in richer countries.
Furthermore, the results of the present study suggest that the
wealth of a country shapes the discussions about new technologies. In
poorer countries, newspaper articles focused more on benefits than on
possible risks; in richer countries, risks were emphasized. Poorer
countries may gain more from additional economic growth, whereas in
richer countries, side effects of additional growth may outweigh
positive effects.
Perception of gene technology varies according to the type of
application. Genetically modified food is less accepted than genetically
altered drugs. 33 Results of the present study further emphasize that
32 See Sokolowska & Tyszka, supra note 16.
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reactions towards gene technology depend on the application. The
wealth of a country explains attitudes towards food-related applications
much better than attitudes towards medical applications. One possible
explanation is that people in richer countries profit less from lower food
production costs than do people in poorer countries; breakthroughs in
drugs, at least in principle, may be equally beneficial for all people.
Each survey provides only a snapshot of prevalent attitudes and
opinions. Research suggesting that genetically modified food could be
potentially harmful, or suggesting that there are unwanted ecological
side effects, may influence public perception of gene technology. 3 4
The theoretical framework of "social amplification of risk" suggests that
social systems may influence the impact new information has on public
perception and responses. 3 5 Data used in the present study were
collected in 1996. Since that time, public discussions about risks and
benefits associated with gene technology have increased in some
European countries. It may well be that this process has weakened the
observed correlations between GNP and attitudes towards
biotechnology.
GNP may explain different levels of acceptance of gene technology
in European countries; it cannot explain, however, why the technology
is more accepted in the United States than in Europe. Other variables
are crucial for the observed cross-national differences regarding
attitudes towards biotechnology. Europe and the United States differ,
for example, in how the technology is regulated and the level of
confidence people have in the regulators.3 6 On an individual level,
social trust had a strong impact on perception of gene technology. 37 It
seems plausible that differences across countries in the level of social
trust in authorities regulating gene technology could be another
explanation for the different levels of acceptance of biotechnology
33 See Siegrist & Biihlmann, supra note 4.
34 See Stanley W. B. Ewen & Arpad Pusztai, Effect of Diets Containing Genetically
Modified Potatoes Expressing Galanthus Nivalis Lectin on Rat Small Intestine, 354 Lancet
1353 (1999); John E. Losey, Linda S. Rayor & Maureen E. Carter, Transgenic Pollen Harms
Monarch Larvae, 399 Nature 214 (1999).
35 See Roger E. Kasperson et al., The Social Amplification of Risk: A Conceptual
Framework, 8 Risk Analysis 177 (1988).
36 See Gaskell et al., supra note 4.
37 See A Causal Model & The Influence of Trust, supra note 5.
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across Europe and the United States. There are, unfortunately, no data
available for testing this hypothesis.
Some limitations of the present study should be mentioned.
Correlations were used for testing the hypotheses presented; thus we
cannot rule out alternative explanations for the strong association
between wealth and perception of gene technology. One possible
explanation could be that cultural factors and not wealth caused
different attitudes towards biotechnology across Europe.
Postmaterialist values were negatively correlated with perceived benefits
and positively correlated with perceived risks of gene technology.3 8
Inglehart and Abramson found a strong association between GNP and
postmaterialist values. 3 9 Therefore, differences in postmaterialist
values, and not GNP, may explain the different attitudes towards
biotechnology across Europe.
The association between wealth of a country and media content was
tested using data provided by Durant et al.4 0 For this content analysis
only higher quality newspapers were analyzed. Other newspapers, news
magazines, radio or TV may report differently about new technologies
than do higher quality newspapers. Furthermore, the analysis was
restricted to European countries. Results of the present study may not
be generalized to other parts of the world.
38 See A Causal Model, supra note 5.
39 Ronald Inglehart & Paul R. Abramson, Economic Security and Value Change, 88 Am.
Pol. Sci. Rev. 336 (1994).
40 See Durant et al., supra note 10.
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